CINCINNATI, Feb. 4 /PRNewswire-FirstCall/ -- Kendle announced today that it will release its fourth quarter 2008 financial results after the market closes on Tuesday, Feb. 24, 2009. The Company will host a telephone conference call and simultaneous webcast on Wednesday, Feb. 25 at 8:30 a.m. Eastern Time. A question and answer session will follow.
Conference Call Instructions
To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on Mar. 25, 2009 by dialing (706) 645-9291 and entering conference ID number 80512141.
Webcast Instructions
To access the live webcast, visit the company Web site at www.kendle.com or link to the Webcast directly at http://www.videonewswire.com/event.asp?id=55622. Instructions for accessing the webcast are provided at both sites. The webcast will be archived at www.kendle.com (click on “Investors” and then “Events & Presentations”) shortly after the call for on-demand replay through 5 p.m. Eastern Time on Mar. 25, 2009. Please note that webcast participants will not be able to ask questions.
System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.
About Kendle
Kendle International Inc. is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world’s biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 99 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers’ clinical development challenges.
Kendle was recognized by FORTUNE magazine as one of the 100 fastest-growing companies in the United States for 2008. The company also has been recognized as, “Top CRO to Work With” in the CenterWatch 2007 survey of U.S. investigative sites and “Best CRO” for 2007 and among the “Top CROs in Europe” in the 2008 survey of European sites.
Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company’s Web site at www.kendle.com.
CONTACT: Michael Lawson, Investors, +1-513-763-1992, or Lori Dorer, Media,
+1-513-345-1685
Web site: http://www.kendle.com/
